RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Sildenafil Citrate for Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion.

Official registry: https://clinicaltrials.gov/study/NCT05061368 · University of Alberta · enrollment listed as 160

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Sildenafil Citrate, or Placebo. The registry lists allocation as randomized. Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction.

They plan to enroll about 160 people at Edmonton. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

The Effect of Oral Sildenafil on Exercise Capacity, Dyspnea and Cardiopulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Sildenafil Citrate, Placebo

Primary outcome (registry wording): Exercise Capacity

Who it is for (from inclusion criteria)

Ages 40 Years to 80 Years
Participants will have COPD as defined as:
Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) below the lower limit of normal
FEV1 \>30% of predicted (lower limit of GOLD severe COPD classification)
COPD Free Controls will have:
No diagnosis of COPD
FEV1 \>80% of predicted

Who the registry excludes

Absolute contraindication to exercise testing or an orthopedic condition that may limit exercise testing
Pre-existing cardiac conditions (heart failure, congenital heart defect, valvular disease) that may limit exercise testing
A diagnosis of pulmonary hypertension preceding COPD
Current phosphodiesterase type-5 inhibitor, nitrate, opioid, azole antifungal, macrolide antibiotic, protease inhibitor, alpha blocker, riociguat, mifepristone or rifamycin use
Pregnancy or lactation
Postmenopausal female participants must be amenorrheic for ≥12 months

Public study contact (from the registry)

Desi Fuhr, MSc

7804921121

fuhr@ualberta.ca

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Clinical Physiology Laboratory — Edmonton, Alberta, Canada (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseNew York, New York

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.

NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

RecruitingNot a traditional drug phaseLumezzane, Brescia

Not a traditional drug phase: Maximal strenght training (MST) plus endurance training (ET) for Chronic Obstructive Pulmonary Disease

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of side effects. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase.

NCT03799354 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

RecruitingNot a traditional drug phaseClermont-Ferrand

Not a traditional drug phase: Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. for Joint Osteoarthritis

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

FAQ about this NCT record

Is NCT05061368 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05061368?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05061368?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary